{{Drugbox
| verifiedrevid = 450332018
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[EpCAM]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 339986-90-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09027
| ChemSpiderID = none
<!-- Chemical data -->
| C=7812 | H=12124 | N=2044 | O=2408 | S=60
| molecular_weight = 175.1 kg/mol
}}

'''Tucotuzumab celmoleukin''' is an anti-[[cancer]] drug. It is a [[fusion protein]] of a [[humanized monoclonal antibody]] (tucotuzumab) and an [[interleukin-2]] (celmoleukin).<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/t_celmoleukin.pdf Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin], ''American Medical Association''.</ref><ref>[http://www.clinicaltrials.gov/ct2/show/NCT00016237 ClinicalTrials.gov]</ref><ref>[http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=456358 National Cancer Institute: Definition of tucotuzumab celmoleukin]</ref>

This drug was developed by [[EMD Pharmaceuticals]].

== References ==
<references/>

{{Monoclonals for tumors}}
{{Interleukin receptor modulators}}

[[Category:Monoclonal antibodies for tumors]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}